Phase I/II study of S 49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma multiforme
Phase of Trial: Phase I/II
Latest Information Update: 10 Apr 2017
At a glance
- Drugs S-49076 (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors IRIS
- 06 Apr 2017 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2016 Preliminary results (n=13) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology